Source: Atherosclerosis. Conference titles: International Symposium on Atherosclerosis. Unidade: FM
Subjects: ENDOCRINOLOGIA, MEDICINA INTERNA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BIGHETTI, E J B et al. Cyprofibrate increases hepatic lipase activity but does not change triglyceride levels in genetic mouse models of dyslipidemias. Atherosclerosis. Amsterdam: Elsevier. . Acesso em: 18 nov. 2024. , 2000APA
Bighetti, E. J. B., Nunes, V. S., Casquero, A. C., Faria, E. C. de, Carneiro, E. M., Boschero, A. C., et al. (2000). Cyprofibrate increases hepatic lipase activity but does not change triglyceride levels in genetic mouse models of dyslipidemias. Atherosclerosis. Amsterdam: Elsevier.NLM
Bighetti EJB, Nunes VS, Casquero AC, Faria EC de, Carneiro EM, Boschero AC, Quintão EC da R, Oliveira HCF. Cyprofibrate increases hepatic lipase activity but does not change triglyceride levels in genetic mouse models of dyslipidemias. Atherosclerosis. 2000 ; 151( 1): 218.[citado 2024 nov. 18 ]Vancouver
Bighetti EJB, Nunes VS, Casquero AC, Faria EC de, Carneiro EM, Boschero AC, Quintão EC da R, Oliveira HCF. Cyprofibrate increases hepatic lipase activity but does not change triglyceride levels in genetic mouse models of dyslipidemias. Atherosclerosis. 2000 ; 151( 1): 218.[citado 2024 nov. 18 ]
